Increased Fat Mass and Obesity Risk After Elexacaftor-tezacaftor-ivacaftor Therapy in Young Adults with Cystic Fibrosis

Overview

Journal Front Nutr

Specialty Nutritional Sciences

Date 2024 Nov 25

PMID 39582664

Authors

Ana Merino Sanchez-Canete

Concepcion Marina Lopez Cardenes

Saioa Vicente Santamaria

Jose Ramon Gutierrez Martinez

Marta Suarez Gonzalez

Maria Alvarez Merino

David Gonzalez Jimenez

Affiliations

Soon will be listed here.

Abstract

Background: When people with cystic fibrosis (PwCFs) are treated with cystic fibrosis transmembrane conductance regulator protein modulator (CFTRm), it leads to changes in body composition. An easy, non-invasive, and reproducible method to assess this is by means of electrical bioimpedance measurement, which complements the information provided by the already-known anthropometric parameters.

Methods: Seventeen adults with cystic fibrosis in treatment with elexacaftor-tezacaftor-ivacaftor (ETI) were recruited for a prospective, longitudinal, single-center study over 12 months. Study variables included weight, body mass index (BMI), and body composition by bioelectrical impedance analysis (BIA) [including fat mass (FM) and fat-free mass (FFM)].

Results: At 12 months, there was an increase in overweight patients (5.9% vs. 23.5%) and a statistically significant increase in BMI at 6 and 12 months. An increase in FM and FFM was observed at 12 months. The increase was greater in FM (95% CI) from a baseline of 1.77% (0.00-3.54; = 0.050) at 6 months and 2.64% (0.48-4.81; = 0.020) at 12 months.

Conclusion: After treatment with ETI, there was an increase in weight, BMI, and FM more than FFM in PwCF. These changes would be confirmed in long-term studies to improve nutritional management.

References

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

Kuriyan R . Body composition techniques. Indian J Med Res. 2019; 148(5):648-658. PMC: 6366261. DOI: 10.4103/ijmr.IJMR_1777_18. View

Goetz D, Savant A . Review of CFTR modulators 2020. Pediatr Pulmonol. 2021; 56(12):3595-3606. DOI: 10.1002/ppul.25627. View

Proud D, Duckers J . Weight a minute: Exploring the effect on weight and body composition after the initiation of elexacaftor/tezacaftor/ivacaftor in adults with CF. J Cyst Fibros. 2023; 22(5):847-850. DOI: 10.1016/j.jcf.2023.06.002. View

King S, Tierney A, Edgeworth D, Keating D, Williams E, Kotsimbos T . Body composition and weight changes after ivacaftor treatment in adults with cystic fibrosis carrying the G551 D cystic fibrosis transmembrane conductance regulator mutation: A double-blind, placebo-controlled, randomized, crossover study with.... Nutrition. 2021; 85:111124. DOI: 10.1016/j.nut.2020.111124. View

Calella P, Valerio G, Brodlie M, Taylor J, Donini L, Siervo M . Tools and Methods Used for the Assessment of Body Composition in Patients With Cystic Fibrosis: A Systematic Review. Nutr Clin Pract. 2019; 34(5):701-714. DOI: 10.1002/ncp.10247. View

Bailey J, Rozga M, McDonald C, Bowser E, Farnham K, Mangus M . Effect of CFTR Modulators on Anthropometric Parameters in Individuals with Cystic Fibrosis: An Evidence Analysis Center Systematic Review. J Acad Nutr Diet. 2020; 121(7):1364-1378.e2. DOI: 10.1016/j.jand.2020.03.014. View

Achamrah N, Colange G, Delay J, Rimbert A, Folope V, Petit A . Comparison of body composition assessment by DXA and BIA according to the body mass index: A retrospective study on 3655 measures. PLoS One. 2018; 13(7):e0200465. PMC: 6042744. DOI: 10.1371/journal.pone.0200465. View

Granados A, Chan C, Moheet A, Vigers T, Arbelaez A, Ode K . The impact of elexacaftor/tezacaftor/ivacaftor on body composition in a small cohort of youth with cystic fibrosis. Pediatr Pulmonol. 2023; 58(6):1805-1811. DOI: 10.1002/ppul.26388. View

10.

De la Hoz D, Villamil Osorio M, Restrepo-Gualteros S . Cystic fibrosis transmembrane conductance regulator modulators: Present and future in cystic fibrosis treatment. A review. Arch Argent Pediatr. 2019; 117(2):e131-e136. DOI: 10.5546/aap.2019.eng.e131. View

11.

Engelen M, Schroder R, Van der Hoorn K, Deutz N, Com G . Use of body mass index percentile to identify fat-free mass depletion in children with cystic fibrosis. Clin Nutr. 2012; 31(6):927-33. DOI: 10.1016/j.clnu.2012.04.012. View

12.

de Castro J, de Lima T, Silva D . Body composition estimation in children and adolescents by bioelectrical impedance analysis: A systematic review. J Bodyw Mov Ther. 2018; 22(1):134-146. DOI: 10.1016/j.jbmt.2017.04.010. View

13.

Wilschanski M, Munck A, Carrion E, Cipolli M, Collins S, Colombo C . ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis. Clin Nutr. 2024; 43(2):413-445. DOI: 10.1016/j.clnu.2023.12.017. View

14.

Schwarzenberg S, Vu P, Skalland M, Hoffman L, Pope C, Gelfond D . Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI. J Cyst Fibros. 2022; 22(2):282-289. PMC: 10144072. DOI: 10.1016/j.jcf.2022.10.003. View

15.

Beaumesnil M, Chaillou E, Wagner A, Rouquette A, Audran M, Ginies J . [Body composition analysis in patients with cystic fibrosis. Comparison of 3 methods: dual energy x-ray absorptiometry, bioelectrical impedance analysis, and skinfold measurements]. Arch Pediatr. 2011; 18(4):370-5. DOI: 10.1016/j.arcped.2011.01.008. View

16.

Alvarez J, Ziegler T, Millson E, Stecenko A . Body composition and lung function in cystic fibrosis and their association with adiposity and normal-weight obesity. Nutrition. 2016; 32(4):447-52. PMC: 4769897. DOI: 10.1016/j.nut.2015.10.012. View

17.

Soltman S, Hicks R, Khan F, Kelly A . Body composition in individuals with cystic fibrosis. J Clin Transl Endocrinol. 2021; 26:100272. PMC: 8586800. DOI: 10.1016/j.jcte.2021.100272. View

18.

Hart N, Tounian P, Clement A, Boule M, Polkey M, Lofaso F . Nutritional status is an important predictor of diaphragm strength in young patients with cystic fibrosis. Am J Clin Nutr. 2004; 80(5):1201-6. DOI: 10.1093/ajcn/80.5.1201. View

19.

Lopes-Pacheco M, Pedemonte N, Veit G . Discovery of CFTR modulators for the treatment of cystic fibrosis. Expert Opin Drug Discov. 2021; 16(8):897-913. DOI: 10.1080/17460441.2021.1912732. View

20.

Nichols D, Paynter A, Heltshe S, Donaldson S, Frederick C, Freedman S . Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. Am J Respir Crit Care Med. 2021; 205(5):529-539. PMC: 8906485. DOI: 10.1164/rccm.202108-1986OC. View